Smith & Nephew plc announced standout results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial (RCT). Published online in Arthroscopy in December, the report concluded that at one-year, medium and large full-thickness rotator cuff tears repaired and augmented with the REGENETEN Bioinductive Implant had better tendon healing compared to the standard of care, as evidenced by: A significantly lower re-tear rate (8.3 vs 25.8%; p=0.01), A three times lower risk of re-tear (RR=0.32; 95% CI:0.13?0.83) and No difference in the number of serious or minor complications. The blinded, multi-centre RCT compared the healing rate of full-thickness rotator cuff tears repaired with and without augmentation with the REGENETEN Bioinductive Implant.

In total, 124 patients with reparable medium and large (1?4cm) full-thickness posterosuperior rotator cuff tears were randomized to receive either an arthroscopic transosseous equivalent double-row rotator cuff repair or the same repair augmented with the REGENETEN Bioinductive Implant. With more than 100,000 procedures completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact, offering a better solution for more than 1 million people having surgery for a rotator cuff tear each year. The collagen-based implant supports the body?s natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.